Gastrointestinal adverse drug reactions to phenprocoumon: Hospital costs and saving potentials;Schwerwiegende arzneimittelnebenwirkungen von phenprocoumon: Stationre kosten der gastrointestinalen blutungen und einsparungspotentiale

PharmacoEconomics - German Research Articles

Volumn 10, Issue 1, 2012, Pages 17-28

  Schwebe, Matthias ^a   Marschall, Paul ^a   Fleßa, Steffen ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; PHENPROCOUMON;

AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALSE POSITIVE RESULT; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENOTYPING TECHNIQUE; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; RURAL AREA;

EID: 84859022932     PISSN: 16123727     EISSN: 1868677X     Source Type: Journal    
DOI: 10.2165/11589830     Document Type: Article

References (67)

1. Bundesministerium fü r Gesundheit und soziale Sicherung. Gesetz ü ber den Verkehr mit Arzneimitteln. y 4 Sonstige Begriffsbestimmungen. 2011
2. Schnurrer JU, Frö lich JC. Zur Häufigkeit und Vermeidbarkeit von tö dlichen unerwü nschten Arzneimittelwirkungen. Internist 2003; 44 (7): 889-95 (Pubitemid 36890019)
3. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 1995; 274 (1): 29-34
4. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5 (3): 305-14 (Pubitemid 28222037)
5. Easton KL, Parsons BJ, Starr M, et al. The incidence of drug-related problems as a cause of hospital admissions in children. Med J Aust 1998; 169 (7): 356-9 (Pubitemid 28486781)
6. Fiss T, Ritter CA, Alte D, et al. Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany. Pharm World Sci 2010; 32 (5): 566-74
7. Wilmer A, Louie K, Dodek P, et al. Incidence of medication errors and adverse drug events in the ICU: a systematic review. Qual Saf Health Care 2010; 19 (5): e7
8. Schneeweiss S, Hasford J, Gö ttler M, et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol 2002; 58 (4): 285-91
9. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring-cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 (Suppl. 3): S79-90 (Pubitemid 27483544)
10. Schalekamp T, Klungel OH, Souverein PC, et al. Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thromb Haemost 2008; 100(6): 1076-83
11. Bussey HI. Transforming oral anticoagulation by combining international normalized ratio (INR) self testing and online automated management. J Thromb Thrombolysis 2011; 31 (3): 265-74
12. McWilliam A, Lutter R, Nardinelli C. Health Care Savings from Personalizing Medicine Using Genetic Testing: TheCase of Warfarin. AEI-BROOKINGS JOINT CENTER FOR REGULATORY STUDIES. 2006
13. Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008; 47(9): 565-94
14. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010; 11(4): 493-6
15. Oldenburg J, BeVans CG, Fregin A, et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98(3): 570-8 (Pubitemid 47421551)
16. Bodin C, Verstuyft DA, Tregouet A, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106 (1): 135-40
17. Schalekamp T, Brasse BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81 (2): 185-93 (Pubitemid 46174815)
18. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113 (4): 784-92
19. Wood S. New Warfarin Labeling Reminds Physicians About Genetic Tests to Help Guide Initial Warfarin Dosing. Medscape Medical News 2007, August
20. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122 (22): 2246-53
21. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154 (1): 1-11
22. Pressemitteilung der AOK Berlin-Brandenburg vom 27.08.2010. AOK Berlin-Brandenburg und AOK Mecklenburg- Vorpommern fusionieren. Erhältlich unter URL: aok-mecklenburg-vorpommern-fusionieren/Forium [Abgerufen am 17.01.12]
23. Statistisches Bundesamt. Verbraucherpreisindex fü r Deutschland. 2010
24. RKI und SBA. Gesundheitsberichterstattung des Bundes 'Gesundheit in Deutschland''. 2007
25. Statistisches Bundesamt. Datenreport 2006. 2006
26. Bundesministerium der Finanzen. AfA-Tabelle fü r die allgemein verwendbaren Anlagegü ter ab 1.1.2001
27. Wyse DG. The AFFIRM trial: main trial and substudies - what can We expect? J Interv Card Electrophysiol 2000; 4 (Suppl. 1): 171-6 (Pubitemid 30236071)
28. Go AS, Hylek EM, Phillips KA, et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 2000; 102 (1): 11-13 (Pubitemid 30430546)
29. Windeler J, Antes G, Behrens J, et al. Randomisierte klinische Studien (RCTF). Z Evid Fortbild Qual Gesundhwes 2008; 102 (5): 321-5
30. Grashoff K. Polypharmazie: Durch Behandlung krank. DAS PTA MAGAZIN 2009; 2: 24-9
31. Van den Bemt PM, Egberts AC, Lenderink AW, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 2000; 22 (2): 62-6 (Pubitemid 30306123)
32. Bufe A, Frey S, Briswalter S. Durch Blutungen verursachte Kosten bei der Therapie des akuten Koronarsyndroms in Deutschland. Herz 2009; 34 (6): 479-84
33. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55 (23): 2556-66
34. AOK-Bundesverband. Vereinbarte Basisfallwerte der DRGKrankenhä user von 2003 bis 2010. 2010
35. Siebig J. Landesweite Basisfallwerte: Wie hoch sind sie und wie geht es weiter? Das Krankenhaus 2005; 7: 559-64
36. Baumol J. Health care, education and the cost disease: A looming crisis for public choic.e. *. Public Choice 1993; 77 (1): 17-28
37. Dykes PC, Wheeler K. Critical Pathways - Interdisziplinäre Versorgungspfade. DRG-Management-Instrumente. Bern: Verlag Hans Huber, 2002
38. Eckman MH, Rosand J, Greenberg SM, et al. Costeffectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150 (2): 73-83
39. Eng CMD, Cossman JMD. New Developments May Change Study Results. Comment on: Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. Ann Intern Med 2009
40. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353 (9154): 717-9 (Pubitemid 29103806)
41. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8 (Pubitemid 34289221)
42. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358 (10): 999-1008 (Pubitemid 351347099)
43. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84 (5): 775-8
44. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352 (22): 2285-93 (Pubitemid 40740552)
45. Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116 (22): 2563-70 (Pubitemid 350179221)
46. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009; 2 (5): 429-36
47. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotypeguided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008; 83 (3): 460-70 (Pubitemid 351272635)
48. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogeneticdata from Chinese patients. J Thromb Thrombolysis 2011; 31 (1): 113-8
49. Griese N, Goebel R, Schulz M. Rabattverträge: harmazeutische Bedenken bei Phenprocoumon? Pharmazeutische Zeitung 15/2010
50. Zimmer Germany GmbH. Auch kü nstliche Gelenke kommen in die Wechseljahre. 26.06.2008
51. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999; 281 (2): 145-50 (Pubitemid 29045346)
52. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost 1999; 25 (1): 103-7
53. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, et al. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost 2004; 2 (4): 584-91
54. Horstkotte D, Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis 2004; 13 (3): 335-8
55. KoertkeH,MinamiK, BoethigD, et al. INRself-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation 2003; 108 (Suppl 1): II75-8
56. McCahon D, Fitzmaurice DA, Murray ET, et al. SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]. BMC Fam Pract 2003; 4: 11
57. Christensen TD, Johnsen SP, Hjortdal VE, et al. Selfmanagement of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol 2007; 118 (1): 54-61 (Pubitemid 46517685)
58. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367 (9508): 404-11 (Pubitemid 43184260)
59. DeMonaco HJ, von Hippel E. Reducing medical costs and improving quality via self-management tools. PLoS Med 2007; 4 (4): e104
60. Lafata JE, Martin SA, Kaatz S, et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. J Thromb Thrombolysis 2000; 9 (Suppl. 1): S13-9 (Pubitemid 30456024)
61. Lafata JE, Martin SA, Kaatz S, et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000; 15 (1): 31-7 (Pubitemid 30060936)
62. Klar HG, Leo-Grö ning I. Selbstmanagement: Patienten messen ihre Blutgerinnung. Pharmazeutische Zeitung. 2004. Erhältlich unter URL: . de/index.php?id=titel-29-2004 [Abgerufen 18.01.2012]
63. Bauman ME, Black KL, Massicotte MP, et al. Accuracy of the CoaguChek XS for point-of-care international normalized ratio (INR) measurement in children requiring warfarin. Thromb Haemost 2008; 99 (6): 1097-103 (Pubitemid 351810492)
64. Newall F, Monagle P, Johnston L. Home INR monitoring of oral anticoagulant therapy in children using the Coagu- Chek S point-of-care monitor and a robust education program. Thromb Res 2006; 118 (5): 587-93 (Pubitemid 44414947)
65. Testa S, Alatri A, Paoletti O, et al. Reorganisation of an anticoagulation clinic using a telemedicine system: description of the model and preliminary results. Intern Emerg Med 2006; 1 (1): 24-9
66. Marstedt G. Patienten-Selbstmanagement: Kostensparend, therapiefö rdernd und trotzdem wenig verbreitet. Forum Gesundheitspolitik vom 17.4.2007. Erhältlich unter URL: ? artikel=0657 [Abgerufen 18.01.2012]
67. Vö ller H, Braun S. Neue Aspekte des INR-Selbstmonitoring. Hamostaseologie 2008; 28 (4): 231-3